Eli Lilly Q1 2026 Earnings: Mounjaro and Zepbound Drive Another Beat as GLP-1 Demand Stays Insatiable

# Eli Lilly Q1 2026 Earnings: Mounjaro and Zepbound Drive Another Beat as GLP-1 Demand Stays Insatiable

> **Quick answer:** Eli Lilly beat Q1 2026 earnings expectations, with Mounjaro and Zepbound continuing to shatter sales records on surging global demand for GLP-1 weight-loss and diabetes drugs. The company reaffirmed its $80–$83 billion full-year 2026 revenue guidance and is on track to launch its first oral GLP-1 pill, Orforglipron, in Q2 2026. LLY stock has been under pressure this year but this report gives bulls new ammunition.

Eli Lilly released its first-quarter 2026 financial results on April 30 before the market open, and Wall Street got another reminder of why the Indianapolis-based drugmaker has become the most dominant force in pharmaceutical history. Analysts were modeling $17.6 billion in revenue and $6.85 in EPS — and Lilly cleared both bars, cementing GLP-1 drugs as the defining commercial story of the decade.

**This article is for informational purposes only and does not constitute financial advice. Consult a qualified financial advisor for personal financial decisions.**

## What the Q1 2026 Numbers Show

Heading into the print, Wall Street had set the bar high: 36.8% year-over-year revenue growth was the consensus expectation, a deceleration from the 45.2% growth Lilly recorded in Q1 2025, but still a pace that almost no $80-billion-revenue company in history has sustained.